- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07748377
Increasing Breast and Colorectal Cancer Screening in the Community
A Pilot Trial of a Community-Based Strategy to Improve Colorectal and Breast Cancer Screening
The goal of the proposed study is to conduct a pilot randomized controlled trial (RCT) of Chi gung, a community-based intervention using peer education and tailored navigation to simultaneously improve colorectal (CRC) and breast cancer (BC) screening rates.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Christina Wang, MD
- Telefoonnummer: 216-702-0789
- E-mail: Christina.Wang@mountsinai.org
Studie Contact Back-up
- Naam: Lili Liang
- Telefoonnummer: 347-270-7705
- E-mail: lili.liang@mssm.edu
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- The Icahn School of Medicine at Mount Sinai
-
Hoofdonderzoeker:
- Christina Wang
-
Contact:
- Christina Wang, MD
- Telefoonnummer: 216-702-0789
- E-mail: Christina.Wang@mountsinai.org
-
Contact:
- Lili Liang
- Telefoonnummer: 347-270-7705
- E-mail: lili.liang@mssm.edu
-
New York, New York, Verenigde Staten, 10002
- Henry Street Settlement
-
Contact:
- Cindy Singh
- Telefoonnummer: 212-766-9200
- E-mail: CSingh@henrystreet.org
-
New York, New York, Verenigde Staten, 10002
- University Settlement
-
Contact:
- Sofiya Pidzyraylo
- Telefoonnummer: 212-475-0150
- E-mail: spidzyraylo@universitysettlement.org
-
New York, New York, Verenigde Staten, 10013
- Charles B. Wang Community Health Center
-
Contact:
- Naumi Feldman
- Telefoonnummer: 212-379-6988
- E-mail: nfeldman@cbwchc.org
-
New York, New York, Verenigde Staten, 10013
- VNS Health Chinatown Community Center
-
Contact:
- Helen Sit
- Telefoonnummer: 917-270-7979
- E-mail: hinglin.sit@vnshealth.org
-
New York, New York, Verenigde Staten, 10038
- St. Margaret's House
-
Contact:
- Claire Guerette
- Telefoonnummer: 212-766-8122
- E-mail: cguerette@smhnyc.org
-
New York, New York, Verenigde Staten, 11223
- United Chinese Association of Brooklyn
-
Contact:
- Ansen Tang
- Telefoonnummer: 929-715-5276
- E-mail: M.tang@ucaob.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Age 45-75 years old
-
Self-identify as Chinese and born outside of the U.S.
-
Speaks Mandarin, Cantonese, or English
-
Not up to date on BC screening (i.e., have not had a mammogram within the past two years)
-
Not up to date on CRC screening (i.e., have not had any of the following tests)
- Colonoscopy within the past 10 years
- Fecal immunochemical tests/fecal occult blood tests within the past year or multi-target stool DNA test within the past three years
- Flexible sigmoidoscopy within the past 5 years
- CT colonography within the past 5 years
Exclusion Criteria:
- Life expectancy ≤ 10 years or other pre-existing conditions whereby CRC or BC screening would not be recommended
- Personal history of BC or CRC
- Prior history of a total colectomy or mastectomy
- Lacks capacity to provide informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Chi gung: Stay Well, Live Well
Chi gung: Stay Well, Live Well is a community-based intervention using peer education and tailored navigation |
The intervention consists of a A) 90-minute group education session led by a community health worker (CHW) that 1) addresses CRC and BC incidence, mortality, development, symptoms, and screening tests, in addition to shared beliefs and common obstacles to CRC and BC screening, 2) involves experiential education (e.g., demonstrations of stool based testing and colonoscopy bowel preparation), 3) question and answer session, and 4) take-home materials summarizing CRC and BC screening information and local resources; and B) peer navigation assistance by telephone to address ongoing obstacles to CRC and BC screening completion, conducted over a 6 month period. The attention control arm will receive a A) time-matched (90-minute) general health didactic on risk factors for cancer and take-home materials on concepts discussed, and B) telephone calls to address concepts covered in the presentation (number of calls will be based on the average frequency of peer navigation calls in the intervention arm). |
|
Actieve vergelijker: Attention Control (AC) Arm
This time-matched and attention control group will receive a general health group education session and follow-up telephone calls. |
The intervention consists of a A) 90-minute group education session led by a community health worker (CHW) that 1) addresses CRC and BC incidence, mortality, development, symptoms, and screening tests, in addition to shared beliefs and common obstacles to CRC and BC screening, 2) involves experiential education (e.g., demonstrations of stool based testing and colonoscopy bowel preparation), 3) question and answer session, and 4) take-home materials summarizing CRC and BC screening information and local resources; and B) peer navigation assistance by telephone to address ongoing obstacles to CRC and BC screening completion, conducted over a 6 month period. The attention control arm will receive a A) time-matched (90-minute) general health didactic on risk factors for cancer and take-home materials on concepts discussed, and B) telephone calls to address concepts covered in the presentation (number of calls will be based on the average frequency of peer navigation calls in the intervention arm). |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Intervention Acceptability Score
Tijdsspanne: 6 Months
|
This will measure whether the participants will accept the intervention. Acceptability will be measured through surveys (likert-rated items) and open-ended questions (semi-structured interviews). The minimum score is 6 and the maximum score is 42; higher scores indicate the intervention is acceptable. |
6 Months
|
|
Number of Navigation Calls
Tijdsspanne: 6 Months
|
This will measure how well the participants can be navigated through the healthcare system and connected to resources using this intervention. Integration will be measured through review of navigation call logs and will include number of navigation calls completed per participant, number of self-reported healthcare visits by the participant, and open-ended questions (semi-structured interviews). |
6 Months
|
|
Intervention Adaptation Score
Tijdsspanne: Baseline, Immediately Post-Education Session, 6 Months
|
This will measure how well the intervention was adapted to address colorectal cancer (CRC) and breast cancer (BC) screening beliefs, benefits, barriers, and self-efficacy. Adaptation will be measured through surveys (likert-rated) and open-ended questions (semi-structured interviews). These measures are investigator-developed subscales informed by the literature. On the beliefs subscale, the minimum score is 17 and the maximum score is 85; higher scores indicate more favorable screening beliefs. On the benefits subscale, the minimum score is 3 and the maximum score is 15; on the barriers subscale, the minimum score is 5 and the maximum score is 25. Higher scores indicate greater perceived benefits and greater perceived barriers, respectively. On the self-efficacy subscale, the minimum score is 8 and the maximum score is 40; higher scores indicate greater self-efficacy to complete screening. |
Baseline, Immediately Post-Education Session, 6 Months
|
|
The Proportion of Participants Who Have Completed Recommended Screening Tests.
Tijdsspanne: 6 Months
|
The proportion of participants who have completed recommended CRC and BC screening tests to assess intervention efficacy. |
6 Months
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Christina Wang, MD, Icahn School of Medicine at Mount Sinai
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Darmziekten
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Intestinale neoplasmata
- Rectale ziekten
- Colon Ziekten
- Huidziektes
- Borst ziekten
- Huid- en bindweefselaandoeningen
- Colorectale neoplasmata
- Borstneoplasmata
Andere studie-ID-nummers
- STUDY-23-01343
- K08CA283362 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD-tijdsbestek voor delen
Immediately following publication. No end date.
IPD-toegangscriteria voor delen
Researchers who provide a methodologically sound proposal. To achieve aims in the approved proposal. Specify Other Mechanism. De-identified public-use data files will be deposited in a data repository and accessible to researchers who agree to the repository's Terms of Use. Restricted-use data files will be available upon execution of a Data Use Agreement approved by the Icahn School of Medicine at Mount Sinai; requests should be directed to the Principal Investigator.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .